Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Biotech ETFs Come Back Down To Earth

Benzinga.com
0 Comments| March 27, 2014

{{labelSign}}  Favorites
{{errorMessage}}

Biotech stocks have been one of the hottest sectors of the market over the last several years and many exchange traded funds have benefitted greatly from their success.

The two largest ETFs in this space are the iShares NASDAQ Biotechnology ETF (NASDAQ: IBB) and SPDR S&P Biotech ETF (NYSE: XBI) -- which have similar underlying companies, but vastly different index construction methodologies.

IBB has nearly $5 billion invested in 123 individual companies that are market cap weighted. This means the companies with the largest market value, such as Amgen (NASDAQ: AMGN) and Biogen Idec (NASDAQ: BIIB), are the largest holdings. In fact, the top 10 holdings in IBB represent nearly 60 percent of the ...

Click to enlargeMore...


{{labelSign}}  Favorites
{{errorMessage}}

Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today

Featured Company